[PDF][PDF] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with …
DA Eberhard, BE Johnson, LC Amler… - Journal of clinical …, 2005 - researchgate.net
DA Eberhard, BE Johnson, LC Amler, AD Goddard, SL Heldens, RS Herbst, WL Ince…
Journal of clinical oncology, 2005•researchgate.netPurpose Epidermal growth factor receptor (EGFR) mutations have been associated with
tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non–
small-cell lung cancer (NSCLC). The implications of EGFR mutations in patients treated with
EGFR inhibitors plus first-line chemotherapy are unknown. KRAS is frequently activated in
NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has
not been described.
tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non–
small-cell lung cancer (NSCLC). The implications of EGFR mutations in patients treated with
EGFR inhibitors plus first-line chemotherapy are unknown. KRAS is frequently activated in
NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has
not been described.
Purpose
Epidermal growth factor receptor (EGFR) mutations have been associated with tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non–small-cell lung cancer (NSCLC). The implications of EGFR mutations in patients treated with EGFR inhibitors plus first-line chemotherapy are unknown. KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described.
researchgate.net
